Heart failure & cardiomyopathies
Baseline Characteristics of Contemporary Trial Participants with Heart Failure and Reduced Ejection Fraction: The VICTOR Trial
Authors' conclusion
The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial.
Study context
- Population
- Patients with heart failure and reduced ejection fraction (HFrEF)
- Participants
- 6,105 patients
- Comparison
- Vericiguat vs placebo
Methodological detailsphase III
- Phase III
Primary result
As reported in the abstract
Baseline characteristics
- Age, mean ± SD (years)
- 67 ± 11
- Women
- 23.6%
- White
- 64.4%
- Self-identified Black
- 10.7%
- Enrolled in Latin and South America
- 29.1%
- Enrolled in Eastern Europe
- 27.8%
- Enrolled in Western Europe
- 18.5%
- Enrolled in Asia-Pacific
- 14.0%
- Enrolled in North America
- 10.6%
- LVEF, mean ± SD
- 30 ± 7%
- NYHA class II
- 79%
- eGFR, mean ± SD (ml/min/1.73 m²)
- 70.9 ± 24.0
- NT-proBNP, median (pg/ml)
- 1476 (970-2495)
- No prior HF hospitalisation
- 47.5%
- Beta-blockers
- 94.4%
- Renin-angiotensin system modulation
- 94.3%
- ARNI
- 56.0%
- MRA
- 77.7%
- SGLT2 inhibitors
- 59.1%
- ICD
- 32.9%
Original publication
Baseline Characteristics of Contemporary Trial Participants with Heart Failure and Reduced Ejection Fraction: The VICTOR Trial. Eur J Heart Fail. Published 16 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →